Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
MRKR Marker Therapeutics
0.369
-0.004-1.07%
Post Mkt Price
0.3690.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Receivable Turnover(T)
-- 3.955 165.43% 2.4759 165.95% 2.4828 165.95% 2.4828
Fixed Assets Turnover(T)
-- 0.0571 29.24% 0.0554 35.45% 0.0573 35.45% 0.0573
Total Asset Rate(T)
-- 0.0187 143.61% 0.0173 115.09% 0.0218 115.09% 0.0218
ROIC
-20.8% -72.008% -30.79% -65.122% -28% -87.757% -28% -87.757%
ROE
-24.52% -90.605% -43.6% -79.500% -46.09% -117.423% -46.09% -117.423%
ROA
-12.94% -62.274% -27.06% -60.020% -17.96% -73.633% -17.96% -73.633%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -186.420% -- --
ROA 5 Year Average
-- -- -- -- -5.37% -156.546% -- --
Average 5 Years ROIC
-- -- -- -- -- -178.578% -- --
Profitability Ratios TTM
Operating Margin
-- -3129.760% 50.93% -3260.967% 48.62% -3179.325% 48.62% -3179.325%
Net Margin
-- -3329.870% 47.84% -3463.766% 45.16% -3372.677% 45.16% -3372.677%
EBITDA Margin
-- -28.6411% 52.17% -29.9984% 50.91% -29.2462% 50.91% -29.2462%
R & D Expense Ratio
-- 2285.810% -47.03% 2349.820% -44.66% 2238.440% -44.66% 2238.440%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 1085.270% -52.87% 1088.810% -53.6% 1040.890% -53.6% 1040.890%
Financial Health Ratios
Long-Term Debt to Equity Ratio
111.06% 38.606% 91.19% 30.908% -41.08% 25.572% -41.08% 25.572%
Total Assets to Common Equity
46.72% 186.681% 26.28% 153.914% -7.14% 154.903% -7.14% 154.903%
Debt to Asset Ratio
115.08% 41.241% 95.16% 32.823% -39.8% 26.983% -39.8% 26.983%
Current Ratio
-79.51% 2.1728 -76.79% 3.7759 -6.53% 3.5641 -6.53% 3.5641
Quick Ratio
-80.58% 1.963 -77.93% 3.4864 -5.99% 3.2826 -5.99% 3.2826
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- 81.993% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
CEO: Mr. Peter L. Hoang
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...